MedTrace Logo

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

NCT02946034 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-11-05

Study results available
· View outcomes & findings →

Summary

Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

Conditions

Interventions

DRUG

Viekira Pak ± ribavirin

12 weeks treatment with AbbVie Viekira Pak ± ribavirin

DRUG

Mavyret

8 or 12 weeks treatment with AbbVie Mavyret

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Raymond T Chung, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-09-16
Completion
2020-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946034 on ClinicalTrials.gov